

Forthcoming Calls for Proposals (10/11)

Barcelona
28 June 2013



Indicative list

Proposed topic	
Call 10	Identification and validation of innovative clinical endpoints for Osteoarthritis
Call 10	European genotype-phenotype repository (EURIPIDES)
Call 10	Correlates of Protection (influenza vaccines)
Call 11	European Platform for Proof-of Concept Trials for Alzheimer Disease (EPOC)
Call 11	Blood-based Biomarker assays for personalized tumor therapy: the value of circulating tumor cells, tumor DNA, and miRNA
Call 11	Zoonoses Anticipation and Preparedness Initiative
Call 11	Identification and clinical validation of new targets
Call 11	European clinical research network for children and adolescents with diabetes and endocrine disorders
Call 11	Consistency of approach for vaccines batch release
Call 10/11	ND4BB: mixed infections, gram-negative/positive, 1-2 clinical studies
Call 10/11	ND4BB: clinical study, paediatric
Call 10/11	Developing Drug-Drug Combinations

* Identification and validation of innovative clinical endpoints for Osteoarthritis

- * Enhance the ability to prospectively identify specific OA patient subsets and enable the ability to conduct focused hypothesis-driven clinical trials

* European genotype-phenotype repository (EURIPIDES)

- * Generate controlled access database (data safe haven) for qualified entities (genotype, phenotype, health records) by linking available data (both 'omic and linked phenotypic) from pharma, government, academics, etc.

* Correlates of Protection (influenza vaccines)

- * Improve and standardise the immunological assays to better evaluate the new and improved influenza vaccines (serological assays and clinically relevant surrogate markers of protection)

* European Platform for Proof-of Concept Trials for Alzheimer Disease (EPOC)

- * We propose to build a European Platform to facilitate Proof of Concept Trials to enable prevention of AD (build registries, longitudinal natural history study to qualify and validate biomarkers, pharmacological intervention trial modelled on SPY-2)

* Blood-based Biomarker assays for personalized tumor therapy: the value of circulating tumor cells, tumor DNA, and miRNA

- * Establishment and clinical validation of methods capturing CRCs in different indications to facilitate development of (companion) diagnostics and (personalized) treatments

* Zoonoses Anticipation and Preparedness Initiative

- * As new outbreaks could spread over large territories in just a few months, the program aim at increasing speed of development of the control tools (less than 6 months after occurrence of new zoonosis)

* Identification and clinical validation of new targets

- * Therapeutic areas/scope under discussion

* European clinical research network for children and adolescents with diabetes and endocrine disorders


- * To develop the paediatric research infrastructure across the EU within the field of diabetes and endocrinology; to develop and implement Paediatric Investigational Plans; design strategies for medicines development – therapeutic areas under discussion

* Consistency of approach for vaccines batch release

- * to make use of technology innovation in the areas of analytical methods, *in vitro* models demonstrating functionality of immune responses, and bioinformatics, and then translate these new technologies to a set of consistency tests that will allow improved monitoring of vaccine quality during production and final formulation

* Developing Drug-Drug Combinations

- * to advance basic research and science on drug-drug combinations enabling a faster, more efficient, and less expensive development process ; to advance the understanding of the underlying health economic aspects

- 
- * ND4BB: mixed infections, gram-negative/positive, 1-2 clinical studies
 - * ND4BB: clinical study, paediatric